Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
The Center of Human Genetics reveals all your secrets

Have a cystic fibrosis or BRCA mutation, or maybe a dangerous variant of the Huntington’s gene  dangling in your cells? The Center of Human Geneti…


Idylla™ : a lab-in-a-box

Janssen and Biocartis are collaborating in order to bring diagnostic  testing closer to the patients. To learn more about the future objectives of…


Multiplicom launches non-invasive test to detect Down's

Multiplicom (Niel) launched a new non-invasive prenatal test (NIPT), Clarigo™, based on a blood sample. Genetic analysis of the baby’s DNA, which …

POPULAR TAGS

Biocartis takes on lung cancer

Written by LVS on in the category news with the tags , .


Biocartis ups its arsenal once again. This time, the company behind the diagnostic Idylla™ platform adds a lung cancer assay to its ever growing menu of diagnostic tests.

Lung cancer comprises 13% of all cancers. The vast majority of these are known as non-small cell lung cancers, many with mutations in the gene encoding the epidermal growth factor receptor (EGFR). Biocartis’ newly launched Idylla™ EGFR Mutation Assay detects up to 53 EGFR mutations in only 150 minutes with 2 minutes of hands-on time. Comparable analyses suffer from a cumbersome workflow which can take several weeks.

With the EGFR Mutation Assay, Biocartis brings its 7th cartridge for the Idylla™ platform to the market. The 5 assays relevant in oncology now cover most of the known and frequently used biomarkers in cancer research and care.

Geert Maertens, Chief Scientific Officer of Biocartis, commented: “Our EGFR Mutation Assay truly is a unique test from various perspectives. Being by far the easiest and fastest test for EGFR mutations available, it detects a broader range of mutations compared to standard tests and only requires a small amount of sample. We see great potential in Europe as well as in Asia where EGFR mutations in NSCLC occur in up to 50% of patients. It is also a great solution both for large reference centers where this new assay is able to complement current workflows in a versatile, fast and cost-effective way, as well as for countries or regions where local accessibility to high precision EGFR testing is limited, or even non-existing. As such, we are convinced this assay will further boost the growth of our installed base of Idylla™ instruments across the globe.”

Read more about: , .

RELATED ARTICLES
The Center of Human Genetics reveals all your secrets

Have a cystic fibrosis or BRCA mutation, or maybe a dangerous variant of the Huntington’s gene  dangling in your cells? The Center of Human Geneti…


Idylla™ : a lab-in-a-box

Janssen and Biocartis are collaborating in order to bring diagnostic  testing closer to the patients. To learn more about the future objectives of…


Multiplicom launches non-invasive test to detect Down's

Multiplicom (Niel) launched a new non-invasive prenatal test (NIPT), Clarigo™, based on a blood sample. Genetic analysis of the baby’s DNA, which …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen Biowin Turnstone V-Bio Ventures KU Leuven Itera Life Science UGent XpandInnovation Flanders.bio GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.